Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders
Report Highlights
The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Frequently Asked Questions (FAQs)
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
